Skip to main content
SpringerLink
Log in

Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The present study aimed to identify the clinical significance of differences in detection timings of left ventricular reverse remodeling (LVRR) on heart failure (HF) prognosis in patients with idiopathic dilated cardiomyopathy (IDCM). We investigated 207 patients with IDCM who underwent pharmacotherapeutic treatment. LVRR was defined as improvements in both LV ejection fraction ≥10 % and indexed LV end-diastolic dimension (LVEDDi) ≥10 %. Patients were stratified into 3 groups by LVRR timing: patients with LVRR <24 months (Early LVRR), those with LVRR ≥24 months (Delayed LVRR), and those without LVRR during the entire follow-up period (No LVRR). The major endpoint was first detection of composite event including readmission for decompensated HF, major ventricular arrhythmias, or all-cause mortality. LVRR was recognized in 108 patients (52 %): Early LVRR in 83 (40 %), Delayed LVRR in 25 (12 %), and No LVRR in 99 (48 %). The survival rate for the major endpoint was significantly higher for Delayed LVRR than for No LVRR (P = 0.001); there was no significant difference between Early and Delayed LVRR. Among patients without LVRR <24 months (Delayed + No LVRR), receiver operating characteristic curve analysis showed that the area under the curve for improvement in LVEDDi during the first 6 months for predicting subsequent LVRR (Delayed LVRR) [0.822 (95 % confidence interval, 0.740–0.916; P = 0.038)] was greater than that for improvement in LVEF. In conclusion, LVRR was a favorable prognostic indicator in patients with IDCM irrespective of its detection timing. Reduced LVEDDi during the first 6 months was predictive for subsequent LVRR in the later phase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569–582

    Article  CAS  PubMed  Google Scholar 

  2. Konstam MA (2005) Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96:867–871

    Article  PubMed  Google Scholar 

  3. Hellawell JL, Margulies KB (2012) Myocardial reverse remodeling. Cardiovasc Ther 30:172–181

    Article  CAS  PubMed  Google Scholar 

  4. Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145:200–202

    Article  PubMed  Google Scholar 

  5. Hori M, Nagai R, Izumi T, Matsuzaki M (2014) Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 29:238–247

    Article  PubMed  Google Scholar 

  6. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR (2003) Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985–1990

    Article  PubMed  Google Scholar 

  7. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, Burkhoff D, Marks AR (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459–2466

    Article  CAS  PubMed  Google Scholar 

  8. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807–2816

    Article  CAS  PubMed  Google Scholar 

  9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e327

    Article  PubMed  Google Scholar 

  10. JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157–2201

    Article  Google Scholar 

  11. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13

    Article  CAS  PubMed  Google Scholar 

  12. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M, Putnikovic B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R, CIBIS-ELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure (2008) Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 97:578–586

    Article  PubMed  Google Scholar 

  13. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G (2011) Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 57:1468–1476

    Article  PubMed  Google Scholar 

  14. Choi JO, Kim EY, Lee GY, Lee SC, Park SW, Kim DK, Oh JK, Jeon ES (2013) Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. Circ J 77:462–469

    Article  PubMed  Google Scholar 

  15. Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M (1999) Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 84:671–676

    Article  CAS  PubMed  Google Scholar 

  16. Ishii S, Inomata T, Ikeda Y, Nabeta T, Iwamoto M, Watanabe I, Naruke T, Shinagawa H, Koitabashi T, Nishii M, Takeuchi I, Izumi T (2014) Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy. Heart Vessels 29:88–96

    Article  PubMed  Google Scholar 

  17. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154–1161

    Article  CAS  PubMed  Google Scholar 

  18. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357–1365

    Article  CAS  PubMed  Google Scholar 

  19. Marsan NA, Bleeker GB, van Bommel RJ, Ypenburg C, Delgado V, Borleffs CJ, Holman ER, van der Wall EE, Schalij MJ, Bax JJ (2009) Comparison of time course of response to cardiac resynchronization therapy in patients with ischemic versus nonischemic cardiomyopathy. Am J Cardiol 103:690–694

    Article  PubMed  Google Scholar 

  20. Verhaert D, Grimm RA, Puntawangkoon C, Wolski K, De S, Wilkoff BL, Starling RC, Tang WH, Thomas JD, Popovic ZB (2010) Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol 55:1788–1795

    Article  PubMed  Google Scholar 

  21. Cross AM Jr, Steenbergen C, Higginbotham MB (1995) Recovery of left ventricular function in acute nonischemic congestive cardiomyopathy. Am Heart J 129:24–30

    Article  PubMed  Google Scholar 

  22. Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, Vrbska J, Malek I, Kautzner J (2013) Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol 61:54–63

    Article  PubMed  Google Scholar 

  23. Udelson JE, Konstam MA (2002) Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 8:S465–S471

    Article  PubMed  Google Scholar 

  24. Bhat PK, Ashwath ML, Rosenbaum DS, Costantini O (2012) Usefulness of left ventricular end-systolic dimension by echocardiography to predict reverse remodeling in patients with newly diagnosed severe left ventricular systolic dysfunction. Am J Cardiol 110:83–87

    Article  PubMed  Google Scholar 

  25. Matsumura Y, Hoshikawa-Nagai E, Kubo T, Yamasaki N, Furuno T, Kitaoka H, Takata J, Sugiura T, Doi Y (2013) Left ventricular reverse remodeling in long-term (>12 years) survivors with idiopathic dilated cardiomyopathy. Am J Cardiol 111:106–110

    Article  PubMed  Google Scholar 

  26. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151–2158

    Article  CAS  PubMed  Google Scholar 

  27. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105:1453–1458

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan

    Yuki Ikeda, Takayuki Inomata, Yuichiro Iida, Miwa Iwamoto-Ishida, Takeru Nabeta, Shunsuke Ishii, Takanori Sato, Tomoyoshi Yanagisawa, Tomohiro Mizutani, Takashi Naruke, Toshimi Koitabashi, Ichiro Takeuchi, Mototsugu Nishii & Junya Ako

Authors
  1. Yuki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Inomata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuichiro Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miwa Iwamoto-Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeru Nabeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunsuke Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takanori Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoyoshi Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomohiro Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Naruke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshimi Koitabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ichiro Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mototsugu Nishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Junya Ako
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takayuki Inomata.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikeda, Y., Inomata, T., Iida, Y. et al. Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. Heart Vessels 31, 545–554 (2016). https://doi.org/10.1007/s00380-015-0648-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-015-0648-2

Keywords

Search

Navigation